UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Annals of oncology, 2023-08, Vol.34 (8), p.670-680

2023

Volltextzugriff (PDF)

Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

Annals of oncology, 2018-10, Vol.29, p.viii612-viii612

2018

Volltextzugriff (PDF)

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118

2019

Volltextzugriff (PDF)

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118-v118

2019

Volltextzugriff (PDF)

1710PClinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625

Annals of oncology, 2014-09, Vol.25, p.iv120

2014

Volltextzugriff (PDF)

362PASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv120-iv120

2014

Volltextzugriff (PDF)

Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT3-1-06-OT3-1-06

2013

Volltextzugriff (PDF)

Chronology of the arterial hypertension associated with inhibiting treatments of vascular endothelium growth factor receptor in patients with cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e19638-e19638

2010

Volltextzugriff (PDF)

CHRONOLOGY OF THE ARTERIAL HYPERTENSION ASSOCIATED WITH GROWTH FACTOR RECEPTOR INHIBITING TREATMENTS DERIVED FROM VASCULAR ENDOTHELIUM IN PATIENTS WITH CANCER: PP.38.503

Journal of hypertension, 2010-06, Vol.28, p.e600

2010

Volltextzugriff (PDF)

P5-14-22: Prospective Observational Study To Describe the Clinicopathological and Biological Characteristics and the Management of Metastatic Breast Cancer Patients Who Experienced Complete or Partial Remission or Disease Stabilization during at Least 3 Years

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-14-22

2011

Volltextzugriff (PDF)

Fluorouracil-induced aphasia

The Annals of pharmacotherapy, 2000-07, Vol.34 (7-8), p.955-955

2000

Volltextzugriff (PDF)

Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia

The Annals of pharmacotherapy, 2001-06, Vol.35 (6), p.785-786

2001

Volltextzugriff (PDF)

A case of 6 different neoplasms

Revista clínica espanõla, 1992-06, Vol.191 (2), p.114

1992

Volltextzugriff (PDF)

A case of 6 different neoplasms

Revista clinica espanola, 1992, Vol.191 (2), p.114-115

1992

Volltextzugriff (PDF)

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Volltextzugriff (PDF)

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project

Nutrients, 2023-01, Vol.15 (2), p.292

2023

Volltextzugriff (PDF)

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2593-2599

2013

Volltextzugriff (PDF)

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Volltextzugriff (PDF)

57TiP SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial

Annals of oncology, 2022-05, Vol.33, p.S146-S147

2022

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(13)
Humans
(12)
Adult
(9)
Oncology
(9)
Female
(8)
Middle Aged
(7)
Aged
(6)
Breast Cancer
(6)
Trasfondo
(6)
Tumors
(6)
Cancer Therapies
(4)
Patients
(4)
Aged, 80 And Over
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Breast Neoplasms - Drug Therapy
(3)
Breast Neoplasms - Pathology
(3)
Cancer
(3)
Chemotherapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

1710PClinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study

Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625

362PASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625

Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC)

Chronology of the arterial hypertension associated with inhibiting treatments of vascular endothelium growth factor receptor in patients with cancer

CHRONOLOGY OF THE ARTERIAL HYPERTENSION ASSOCIATED WITH GROWTH FACTOR RECEPTOR INHIBITING TREATMENTS DERIVED FROM VASCULAR ENDOTHELIUM IN PATIENTS WITH CANCER: PP.38.503

P5-14-22: Prospective Observational Study To Describe the Clinicopathological and Biological Characteristics and the Management of Metastatic Breast Cancer Patients Who Experienced Complete or Partial Remission or Disease Stabilization during at Least 3 Years

Fluorouracil-induced aphasia

Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia

A case of 6 different neoplasms

A case of 6 different neoplasms

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Pembrolizumab for Early Triple-Negative Breast Cancer

Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

57TiP SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial

Suchergebnisse filtern